Skip to main content
Top
Published in: Journal of Nephrology 4/2020

01-08-2020 | Tocilizumab | Lessons for the clinical nephrologist

Recurrent antibody-mediated rejection in renal allograft: physician’s dilemma

Authors: Suman Krishna Kotla, Bekir Tanriover

Published in: Journal of Nephrology | Issue 4/2020

Login to get access

Abstract

Antibody-mediated rejection is the primary cause of renal allograft failure, and the molecular mechanistic is relatively less known in comparison to cell-mediated rejection. With the advent of new immunological agents, the short-term graft survival outcomes have improved, but the long-term outcomes are still unchanged. We present a case of 47-year-old with end-stage renal disease due to presumed lupus status post deceased donor renal transplantation. The patient developed recurrent (a total of five) antibody-mediated rejections (donor-specific antibody and C4d staining negative) spanning within a year of transplant despite the standard of care therapies. The present case draws attention to the importance of non-HLA antibodies in antibody-mediated rejection and diagnostic tools we can rely on when the histology is inconclusive and the role of new immunological agents.
Literature
1.
go back to reference Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS (1970) Humoral antibodies in renal allotransplantation in man. N Engl J Med 282(3):111–117CrossRef Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS (1970) Humoral antibodies in renal allotransplantation in man. N Engl J Med 282(3):111–117CrossRef
2.
go back to reference Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK (2011) Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 12(4):579–592CrossRef Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK (2011) Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 12(4):579–592CrossRef
3.
go back to reference Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R et al (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352(6):558–569CrossRef Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R et al (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352(6):558–569CrossRef
4.
go back to reference Giral M, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A et al (2013) Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 13(10):2567–2576CrossRef Giral M, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A et al (2013) Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 13(10):2567–2576CrossRef
5.
go back to reference Mifune M, Sasamura H, Nakazato Y, Yamaji Y, Oshima N, Saruta T (2001) Examination of angiotensin II type 1 and type 2 receptor expression in human kidneys by immunohistochemistry. Clin Exp Hypertens 23(3):257–266CrossRef Mifune M, Sasamura H, Nakazato Y, Yamaji Y, Oshima N, Saruta T (2001) Examination of angiotensin II type 1 and type 2 receptor expression in human kidneys by immunohistochemistry. Clin Exp Hypertens 23(3):257–266CrossRef
6.
go back to reference Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P et al (2017) Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol 28(7):2221–2232CrossRef Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P et al (2017) Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol 28(7):2221–2232CrossRef
7.
go back to reference Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D et al (2017) Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. Am J Transplant 17(11):2851–2862CrossRef Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D et al (2017) Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. Am J Transplant 17(11):2851–2862CrossRef
8.
go back to reference Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T et al (2014) Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 25(10):2267–2277CrossRef Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T et al (2014) Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 25(10):2267–2277CrossRef
9.
go back to reference Pearl MH, Grotts J, Rossetti M, Zhang Q, Gjertson DW, Weng P et al (2019) Cytokine profiles associated with angiotensin II Type 1 receptor antibodies. Kidney Int Rep 4(4):541–550CrossRef Pearl MH, Grotts J, Rossetti M, Zhang Q, Gjertson DW, Weng P et al (2019) Cytokine profiles associated with angiotensin II Type 1 receptor antibodies. Kidney Int Rep 4(4):541–550CrossRef
10.
go back to reference Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D et al (2017) Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17(9):2381–2389CrossRef Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D et al (2017) Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17(9):2381–2389CrossRef
11.
go back to reference Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L et al (2018) De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant 18(7):1783–1789CrossRef Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L et al (2018) De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant 18(7):1783–1789CrossRef
12.
go back to reference Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M et al (2019) Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ 366:l4923CrossRef Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M et al (2019) Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ 366:l4923CrossRef
13.
go back to reference Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL et al (2018) Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection. J Am Soc Nephrol. 29(2):606–619CrossRef Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL et al (2018) Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection. J Am Soc Nephrol. 29(2):606–619CrossRef
Metadata
Title
Recurrent antibody-mediated rejection in renal allograft: physician’s dilemma
Authors
Suman Krishna Kotla
Bekir Tanriover
Publication date
01-08-2020
Publisher
Springer International Publishing
Keyword
Tocilizumab
Published in
Journal of Nephrology / Issue 4/2020
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-020-00780-7

Other articles of this Issue 4/2020

Journal of Nephrology 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine